论文部分内容阅读
目的:对盐酸氨溴索静滴联合糜蛋白酶雾化在支气管肺炎中的治疗效果进行分析和探讨。方法:此次临床研究主要以我院在2010年1月~2012年1月收治的60例支气管肺炎患儿为研究对象,采用随机分配的原则,将两组患儿分成对照组和实验组,每个组别30例。对照组采用常规方法进行治疗,实验组在对照组的常规方法上增加盐酸氨溴索静滴联合糜蛋白酶雾化治疗,对两组患儿的临床效果进行观察和比较。结果:经临床研究结果显示,实验组的临床疗效明显优于对照组,肺部啰音消失时间以及气促改善时间明显短于对照组,差异存在统计学意义,P<0.05。结论:经临床研究结果表明,采用盐酸氨溴索静滴联合糜蛋白酶雾化对支气管肺炎患儿进行治疗,效果显著,具有较高的临床应用价值,值得推广和普及。
Objective: To analyze and discuss the therapeutic effect of intravenous ambroxol hydrochloride combined with chymotrypsin atomization in bronchial pneumonia. Methods: The clinical study mainly included 60 children with bronchopneumonia treated in our hospital from January 2010 to January 2012. The children were divided into control group and experimental group according to the principle of random distribution. 30 cases in each group. The control group was treated by conventional method. In the control group, ambroxol hydrochloride combined with chymotrypsin atomization was added to the conventional method in the control group. The clinical effects of the two groups were observed and compared. Results: The results of clinical studies showed that the clinical efficacy of the experimental group was significantly better than the control group, the pulmonary rales disappeared time and shortening improvement time was significantly shorter than the control group, the difference was statistically significant (P <0.05). Conclusion: The results of clinical studies show that the use of ambroxol hydrochloride intravenous infusion combined with chymotrypsin in children with bronchial pneumonia treatment, the effect is significant, with high clinical value, it is worth promoting and universal.